FTC Sues to Block Cencora's $3.5B Veterinary Unit Sale to Covetrus

What happened

The Federal Trade Commission filed suit in New York federal court to block Cencora's planned $3.5 billion sale of its MWI Animal Health unit to Covetrus, arguing the transaction would reduce competition and raise costs for veterinary clinics and pet owners. Cencora had agreed to divest MWI as part of its strategic pivot toward higher-margin specialty and oncology services, and the sale was expected to provide significant cash proceeds to reduce debt and fund further acquisitions. The FTC's challenge introduces substantial uncertainty about whether the divestiture will close at all, or whether it may require remedies or be terminated, disrupting Cencora's capital allocation plans. This development comes as Cencora already faces integration costs from OneOncology and AON acquisitions, with leverage elevated and operating margins thin, making the loss of expected cash particularly unwelcome. Investors will need to reassess the company's deleveraging timeline and balance sheet flexibility until the litigation resolves.

Implication

Near-term, the stock may underperform as investors discount the probability of the MWI sale completing on original terms, removing a key source of expected cash. The blocked sale prolongs elevated leverage and limits management's ability to fund additional oncology acquisitions or buybacks, potentially slowing the specialty-platform expansion narrative. However, the core thesis remains tied to Cencora's oncology platform growth and integration execution, not the veterinary divestiture; veterinary was a non-core asset and its sale was always secondary. The WAIT rating stands, with entry below $295 now looking more attractive if the stock dips on this news, but the thesis delta is slightly negative due to reduced financial flexibility. Key monitoring: any FTC settlement or abandonment of the deal, revised cash deployment plans, and whether Cencora reinitiates a sale process for MWI after litigation concludes.

Thesis delta

The WAIT thesis is modestly weakened by the FTC's challenge to the MWI sale. Previously, the thesis assumed the $3.5B divestiture would reduce debt and fund oncology growth; now that cash inflow is uncertain, potentially delaying deleveraging and limiting capital flexibility. Core specialty-oncology thesis is unchanged, but the near-term financial trajectory is more clouded.